Thursday, November 12, 2026

Ripple On Bearish Momentum: 0% Down In The Last 6 Hours

ViaNews Editorial Team

December 27, 2020

Ripple On Bearish Momentum: 0% Down In The Last 6 Hours

Ripple is currently on bearish momentum. At 11:09 EST on Sunday, 27 December, Ripple is at $0.30 and down by 0% in the last 6 hours.

Ripple Range

Over the last six hours, Ripple's higher value was $0.30 and the lower value was $0.28.

Over the last twelve hours, Ripple's higher value was $0.30 and the lower value was $0.28.

About Ripple's daily highs and lows, it's 7.143% up from its trailing 24-hour low of $0.28 and 3.226% down from its trailing 24-hour high of $0.31.

Regarding Ripple's yearly highs and lows, it's 160.643% up from its 52-week low and 60.938% down from its 52-week high.

Volatility

Ripple's last day and last week average volatility is a negative 7.94% and a positive 13.52%, respectively. Ripple's high and low amplitude percentage in the last week was 27.29%.

News about Bitcoin

 michael saylor, the CEO who turned a software company into a Bitcoin company. According to Bloomberg Quint on Thu Dec 24, "Then, as Bitcoin ran up, it bought more, and the stock has now soared thanks to the bet. ", "This past summer, the business intelligence software company MicroStrategy made waves when it put some of its extra cash into Bitcoin. "

Bitcoin rally has already outlasted 2017 run. According to The Wall Street Journal on Thu Dec 24, "Bitcoin bulls say the money fueling this year's rally is coming from more reliable sources than past rallies. "

Bitcoin crushes doubters as 224% rally proves it’s here to stay. According to Bloomberg Quint on Thu Dec 24, "There has been no substantial progress made on Bitcoin as a unit of exchange. ", "Since Bitcoin's market capitalization reached $1 billion in March 2013, there have been two cycles of spikes to record highs, followed by drawdowns of more than 80%. "

Luxxfolio to acquire 590 Bitcoin miners. According to Business Insider on Thu Dec 24,

Bitcoin surges to fresh record high and looks set to break the $25,000 level: 'merry bitmas'. According to Business Insider on Fri Dec 25, "However, Bitcoin investors - known for their unquenchable optimism - think this is just the start.", "Known as the leading cryptocurrency, Bitcoin has been a surprise success during the pandemic, quickly becoming a competitor to gold in some portfolios."

Bitcoin miners in nordic region get a boost from cheap power. According to Bloomberg Quint on Sun Dec 27, ""We have seen a notable up-tick in investor appetite for Bitcoin mining opportunities in Norway," said Tyler Page, a business developer at Bitfury. ", "The resulting glut in the most important raw material for making the virtual coins coincided with a year when the price of Bitcoin tripled."

Bitcoin faces regulatory scrutiny after record-breaking rally. According to Bloomberg Quint on Sun Dec 27, "Janet Yellen, who's been nominated to serve as Treasury secretary in Biden's administration, has in recent years cautioned investors over Bitcoin, saying it was a "highly speculative asset" and "not a stable store of value." A representative didn't immediately return a request seeking comment.", ""What's happening now -- and it's happening faster than anyone could ever imagine -- is that Bitcoin is moving from a fringe esoteric asset to the mainstream," said Matt Hougan, chief investment officer of Bitwise Asset Management. "

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,565 source documents archived
Query this data → isubstrate.com